Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3-5 chronic kidney disease undergoing mri with injected gadobenate dimeglumine or gadoteridol

American Journal of Roentgenology

Volumn 205, Issue 3, 2015, Pages 469-478

  Soulez, Gilles ^a   Bloomgarden, Daniel C ^b,c   Rofsky, Neil M ^d,e   Smith, Martin P ^d   Abujudeh, Hani H ^f   Morgan, Desiree E ^g   Lichtenstein, Richard J ^h   Schiebler, Mark L ⁱ   Wippold Ii, Franz J ^j   Russo, Craig ^k   Kuhn, Matthew J ^l,m   Mennitt, Kevin W ⁿ   Maki, Jeffrey H ^o,p   Stolpen, Alan ^q   Liou, Johnson ^r   Semelka, Richard C ^s   Kirchin, Miles A ^t   Shen, Ningyan ^u   Pirovano, Gianpaolo ^u   Spinazzi, Alberto ^u  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ST LUKE S MEDICAL CENTER   (United States)

^c St Joseph's Hospital   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^h SARASOTA MEMORIAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k SC   (United States)

^l ST JOHN'S HOSPITAL   (United States)

^m UNIVERSITY OF ILLINOIS   (United States)

ⁿ WEILL CORNELL MEDICAL COLLEGE   (United States)

^o VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^p UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^q UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^r Radiology Association of Atlanta   (United States)

^s UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^t Bracco Imaging SpA   (Italy)

^u Bracco Research USA   (United States)

more..

Author keywords

Gadobenate dimeglumine; Gadoteridol; Nephrogenic systemic fibrosis; Prospective studies

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOTERIDOL; CONTRAST MEDIUM; GADOBENIC ACID; GADOLINIUM; HETEROCYCLIC COMPOUND; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; AGITATION; ARTICLE; BURNING SENSATION; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; FEMALE; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HYPERSENSITIVITY; IMAGE ANALYSIS; IMAGE QUALITY; INCIDENCE; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SEVERE RENAL IMPAIRMENT; SIDE EFFECT; SNEEZING; URTICARIA; VOMITING; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; KIDNEY FUNCTION TEST; MIDDLE AGED; MULTICENTER STUDY; NEPHROGENIC FIBROSING DERMOPATHY; POSTMARKETING SURVEILLANCE; RISK FACTOR;

ADOLESCENT; ADULT; AGED; CONTRAST MEDIA; FEMALE; GADOLINIUM; HETEROCYCLIC COMPOUNDS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; ORGANOMETALLIC COMPOUNDS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84942693350     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.14.14268     Document Type: Article

References (52)

1. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23:383-393
2. Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011; 65:1095-1106
3. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356:1000-1001
4. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:3604-3605 [Erratum in Nephrol Dial Transplant 2006; 21:1745]
5. Spinazzi A. MRI contrast agents and nephrogenic systemic fibrosis. In: Shellock FG, Crues JV, eds. MRI bioeffects, safety, and patient management [chapter 11]. Playa del Rey, CA: Biomedical Research Publishing Group, 2014
6. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(suppl 1):S1-S266
7. Heverhagen JT, Krombach GA, Gizewski E. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis. Rofo 2014; 186:661-669
8. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007; 2:264-267
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470
10. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58:259-263
11. Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984; 104:849-854
12. Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 1985; 106:522-526
13. Bryant BJ 2nd, Im K, Broome DR. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Clin Radiol 2009; 64:706-713
14. Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008; 3:747-751
15. Abujudeh HH, Rolls H, Kaewlai R, et al. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging 2009; 30:1335-1340
16. Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER 3rd, Semelka RC. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy-report from two U.S. universities. Radiology 2009; 253:689-696
17. Martin DR, Krishnamoorthy SK, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010; 31:440-446
18. Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL. Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function? Radiology 2015 Apr 15:142423 [Epub ahead of print]
19. Elmholdt TR, Olesen AB, Jørgensen B, et al. Nephrogenic systemic fibrosis in Denmark-a nationwide investigation. PLoS ONE 2013; 8:e82037 [Erratum in PLoS One 2014; 9:e100407] PubMed
20. Penfield JG, Reilly RF. Nephrogenic systemic fibrosis risk: is there a difference between gadoliniumbased contrast agents? Semin Dial 2008; 21:129-134
21. Idée JM, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: a critical update. Crit Rev Toxicol 2014; 44:895-913
22. Thakral C, Abraham JL. Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis. J Cutan Pathol 2009; 36:1244-1254
23. George SJ, Webb SM, Abraham JL, Cramer SP. Synchrotron X-ray analyses demonstrate phosphatebound gadolinium in skin in nephrogenic systemic fibrosis. Br J Dermatol 2010; 163:1077-1081
24. van der Molen AJ. Nephrogenic systemic fibrosis and the role of gadolinium contrast media. J Med Imaging Radiat Oncol 2008; 52:339-350
25. Kaewlai R, Abujudeh H. Nephrogenic systemic fibrosis. AJR 2012; 199:[web]W17-W23
26. Shellock FG, Spinazzi A. MRI safety update 2008. Part 1 MRI contrast agents and nephrogenic systemic fibrosis. AJR 2008; 191:1129-1139
27. Swan SK, Lambrecht LJ, Townsend R, et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 1999; 34:443-448
28. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998; 5:491-502
29. Tombach B, Bremer C, Reimer P, et al. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol 2000; 35:35-40
30. Rofsky NM, Sherry AD, Lenkinski RE. Nephrogenic systemic fibrosis: a chemical perspective. Radiology 2008; 247:608-612
31. Idée JM, Port M, Robic C, Medina C, Sabatou M, Corot C. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 2009; 30:1249-1258
32. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006; 1:128-137
33. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol 2006; 41:222-228
34. Shen Y, Goerner FL, Snyder C, et al. T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Invest Radiol 2015; 50:330-338
35. Seidl Z, Vymazal J, Mechl M, et al. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR 2012; 33:1050-1058
36. Martincich L, Faivre-Pierret M, Zechmann CM, et al. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for breast MR imaging (DETECT trial). Radiology 2011; 258:396-408
37. Gerretsen SC, le Maire TF, Miller S, et al. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. Radiology 2010; 255:988-1000
38. de Campos RO, Heredia V, Ramalho M, et al. Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations. AJR 2011; 196:545-552
39. Khouri Chalouhi K, Papini GD, Bandirali M, Sconfienza LM, Di Leo G, Sardanelli F. Less is better? Intraindividual and interindividual comparison between 0.075 mmol/kg of gadobenate dimeglumine and 0.1 mmol/kg of gadoterate meglumine for cranial MRI. Eur J Radiol 2014; 83:1245-1249
40. Duke University Health System. Policy statement regarding the use of gadolinium based contrast agents in research. Duke University website. irb. duhs.duke.edu/wysiwyg/downloads/Gadolinium- Risk-Policy-R06-06-08.pdf. Published June 6, 2008. Accessed September 4, 2014
41. Department of Radiology, University of North Carolina (UNC) School of Medicine. Policy on radiologic intravascular contrast. UNC website. www.med.unc.edu/radiology/files-a/protocols/UNC%20 Radiology%20Intravascular%20Contrast%20 Protocol%20with%20addendum%20May%2026% 202010.pdf. Published February 1, 2007. Accessed September 4, 2014
42. American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR website. ACR manual on contrast media, version 9. www.acr. org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2013-Contrast- Media.pdf. Published 2013. Accessed December 11, 2014
43. Wang Y, Alkasab TK, Narin O, et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011; 260:105-111
44. Caravan P, Comuzzi C, Crooks W, McMurry TJ, Choppin GR, Woulfe SR. Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging. Inorg Chem 2001; 40:2170-2176
45. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 1999; 6:282-291
46. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008; 43:141-144
47. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008; 248:807-816
48. Kirchin MA, Lorusso V, Pirovano G. Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis? Br J Radiol 2015; 88:20140526
49. Hanna RF, Finkelstone LA, Chow DS, et al. Nephrogenic systemic fibrosis risk and liver disease. Int J Nephrol 2014; 2014:679605
50. Smorodinsky E, Ansdell DS, Foster ZW, et al. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. J Magn Reson Imaging 2015; 41:1259-1267
51. Shaffer KM, Parikh MR, Runge TM, Perez SD, Sakaria SS, Subramanian RM. The renal safety of intravenous gadolinium enhanced magnetic resonance imaging in patients awaiting liver transplantation. Liver Transpl 2015 Mar 18 [Epub ahead of print]
52. Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008; 21:123-128